autologous peripheral blood lymphocytes from ibrutinib-treated chronic lymphocytic leukemia patients iov-2001
Generic: Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001
autologous peripheral blood lymphocytes from ibrutinib-treated chronic lymphocytic leukemia patients iov-2001: 1 clinical trial tracked.
autologous peripheral blood lymphocytes from ibrutinib-treated chronic lymphocytic leukemia patients iov-2001 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about autologous peripheral blood lymphocytes from ibrutinib-treated chronic lymphocytic leukemia patients iov-2001, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Primary endpoint: Phase I: RP2D (Recommended Phase 2 Dose)
Interventionalopen7 enrolledStarted 2020-02Completion 2024-127 sites · United StatesIovance Biotherapeutics, Inc.